Editas Medicine (EDIT) Q2 2024 earnings summary

Executive summary

• Achieved significant progress in Q2 2024, advancing reni-cel (gene-edited cell therapy) toward BLA and commercialization, with robust clinical data for sickle cell disease and beta thalassemia, and strengthening the in vivo gene editing pipeline.

• Completed adolescent and adult cohort enrollment in both RUBY (SCD) and EdiTHAL (TDT) trials, with ongoing dosing, manufacturing improvements, and no serious adverse events related to reni-cel.

• Strategic partnerships and collaborations, including BMS, Vertex, and Vor Bio, offer significant license and milestone payment potential.

• Remain on track to establish in vivo preclinical proof of concept for an undisclosed indication by year-end.

• As of June 30, 2024, the company had an accumulated deficit of $1.4 billion and expects to continue incurring significant operating losses.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $318.3 million as of June 30, 2024, down from $376.8 million at March 31, 2024, due to increased R&D and manufacturing expenses.

• Revenue for Q2 2024 was $0.5 million, down 82% year-over-year, primarily due to reduced drug supply activity with collaborators.

• Net loss for Q2 2024 was $67.6 million ($0.82/share), a 68% increase compared to Q2 2023.

• Research and development expenses rose 82% year-over-year to $54.2 million in Q2 2024, driven by reni-cel and in vivo research.

• General and administrative expenses increased to $18.2 million in Q2 2024, mainly due to higher IP, legal, and facility costs.

Outlook and guidance

• Additional clinical data from RUBY and EdiTHAL trials expected by year-end 2024.

• In vivo preclinical proof of concept data for a new indication anticipated by year-end.

• Cash runway, including anticipated license fees and contingent payments, expected to fund operations into 2026.

• The company anticipates continued increases in expenses as it advances clinical and preclinical programs.

• Ongoing evaluation of partnering and licensing opportunities to optimize commercialization and capital efficiency.